JPH01113067A - Separation of plasma - Google Patents
Separation of plasmaInfo
- Publication number
- JPH01113067A JPH01113067A JP62270718A JP27071887A JPH01113067A JP H01113067 A JPH01113067 A JP H01113067A JP 62270718 A JP62270718 A JP 62270718A JP 27071887 A JP27071887 A JP 27071887A JP H01113067 A JPH01113067 A JP H01113067A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- blood
- line
- pressure
- separation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000926 separation method Methods 0.000 title claims abstract description 35
- 210000004369 blood Anatomy 0.000 claims abstract description 23
- 239000008280 blood Substances 0.000 claims abstract description 23
- 239000012528 membrane Substances 0.000 claims abstract description 22
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 3
- 230000036770 blood supply Effects 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 239000003146 anticoagulant agent Substances 0.000 abstract description 4
- 229940127219 anticoagulant drug Drugs 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract 1
- 239000012510 hollow fiber Substances 0.000 description 15
- 210000000601 blood cell Anatomy 0.000 description 10
- 206010018910 Haemolysis Diseases 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 238000007873 sieving Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229920000098 polyolefin Polymers 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 210000001724 microfibril Anatomy 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002090 carbon oxide Inorganic materials 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- DNTNDFLIKUKKOC-UHFFFAOYSA-N gabexate methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は血漿分離膜により血液から赤血球、白血球およ
び血小板よりなる血球成分と、血漿成分とを効果的に分
離する血漿分離方法に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a plasma separation method for effectively separating blood cell components consisting of red blood cells, white blood cells and platelets from blood and plasma components using a plasma separation membrane.
［従来の技術］
近年になって、プラズマフェレーシスと呼ばれる血漿分
離法が開発されつつある。この血漿分離法は、血液をま
ず血漿成分と血球成分に分離し、血漿成分を各種手段で
処理して疾病因子を除去するものであり、このような血
漿分離法には、例えば、
■血液を血漿分離膜を介して血漿成分と血球成分に分離
した後、疾病因子を含む血漿成分を排出し、血球成分の
み、あるいは血漿成分と同量の人工血漿を血球成分と混
合して採血者の体内に返還する方法、
■血液を血漿分離膜を介して血漿成分と血球成分に分離
した後、疾病因子を含む血漿成分を吸着剤と接触させて
疾病因子を吸着除去し、次いでその血漿成分を血球成分
と再び混合して採血者の体内に返還する方法、
などが提案されている。[Prior Art] In recent years, a plasma separation method called plasmapheresis has been developed. This plasma separation method first separates blood into plasma components and blood cell components, and then processes the plasma components using various means to remove disease factors. After separating plasma components and blood cell components through a plasma separation membrane, the plasma components containing disease factors are discharged, and either only the blood cell components or the same amount of artificial plasma as the plasma components are mixed with the blood cell components and then injected into the blood donor's body. After blood is separated into plasma components and blood cell components through a plasma separation membrane, the plasma components containing disease factors are brought into contact with an adsorbent to adsorb and remove disease factors, and then the plasma components are separated into blood cells. A method has been proposed in which the blood is mixed with other components and returned to the body of the person collecting the blood.
このような各分離法を実施するためにはいずれの場合も
血液を血漿成分と血球成分とに効果的に分離することが
必要である。そして、通常、血漿分離法においてはその
濾過圧が膜間圧力差により定義されている。ここで膜間
圧力差（ｐＴ）は、下記式で示されるものである。In order to carry out each of these separation methods, it is necessary to effectively separate blood into plasma components and blood cell components. In plasma separation methods, the filtration pressure is usually defined by the transmembrane pressure difference. Here, the transmembrane pressure difference (pT) is expressed by the following formula.
ｐＴ ＝ （（Ｐ、＋Ｐ２ ）／２）−Ｐ３（式中
、Ｐｌは血漿分離器の血液入口側の圧力、Ｐ２は血漿分
離器の血球成分出口側の圧力、およびＰ３は血漿分離器
の濾液（血漿成分）側圧力を指す。）
従来、溶血防止の観点から、血漿分離操作における膜間
圧力差を一定以上（通常、５０〜１００ｍ ｍ Ｈｇ程
度以下）に上昇しないよう制御する手段が提案されてい
る。（特開昭５９−１７７０５８号公報及び特開昭６１
−８５９５１号公報）［発明か解決しようとする問題点
］
しかしながら、上記従来の技術にあっては溶血は防止で
きるものの、膜間圧力差を１００ｍｍＨｇ程度以下に維
持しているため、総蛋白、ＩｇＭ等の篩い係数が多少劣
るものであった。pT = ((P, +P2)/2)-P3 (where Pl is the pressure on the blood inlet side of the plasma separator, P2 is the pressure on the blood cell component outlet side of the plasma separator, and P3 is the filtrate of the plasma separator) (Plasma component) side pressure) Conventionally, from the perspective of preventing hemolysis, means have been proposed to control the transmembrane pressure difference in plasma separation operations so that it does not rise above a certain level (usually about 50 to 100 mm Hg or less). ing. (Unexamined Japanese Patent Publications No. 59-177058 and Unexamined Japanese Patent Publication No. 61
-85951 Publication) [Problems to be Solved by the Invention] However, although the above-mentioned conventional techniques can prevent hemolysis, the transmembrane pressure difference is maintained at about 100 mmHg or less, so total protein, IgM The sieving coefficient was somewhat inferior.
［問題点を解決するための手段］
そこで、本発明者は溶血を防止しつつ、総蛋白等の篩い
係数を改善し得る血漿分離法について、種々の角度から
検討したところ、濾過圧を膜間圧力差てなく濾液側の圧
力という観点からみた場合、血漿ライン側、即ち、濾液
側の圧力を防圧に保持すると、上記目的を達成できるこ
とを見出し、本発明に到達した。[Means for Solving the Problems] Therefore, the present inventor investigated from various angles a plasma separation method that can improve the sieving coefficient of total protein while preventing hemolysis. When viewed from the viewpoint of the pressure on the filtrate side without any pressure difference, the inventors have discovered that the above object can be achieved by maintaining the pressure on the plasma line side, that is, the filtrate side, at a pressure-proof level, and have arrived at the present invention.
即ち、本発明によれば、血漿分離膜を内蔵した血漿分離
器と、該血漿分離器へ血液を輸送する送血ラインと、前
記血漿分離器において血漿が分離された赤血球濃厚液を
返送する返血ラインと、前記分離された血漿を輸送する
血漿ラインとからなる血漿分離系における血漿分離に際
し、前記血漿ライン側圧力を防圧に保持することを特徴
とする血漿分離方法、が提供される。That is, according to the present invention, a plasma separator having a built-in plasma separation membrane, a blood supply line for transporting blood to the plasma separator, and a return system for returning the red blood cell concentrate from which plasma has been separated in the plasma separator are provided. There is provided a plasma separation method characterized in that during plasma separation in a plasma separation system consisting of a blood line and a plasma line for transporting the separated plasma, the pressure on the plasma line side is maintained at a pressure-proof level.
本発明では、血漿分離操作に際し、通常実施されている
程度の濾過圧（即ち、膜間圧力差）と全く異なった範囲
の圧力にて分離操作を行なうことにその特徴を有してお
り、しかもその圧力においても血球成分の破壊（即ち、
溶血）が生じないのである。The present invention is characterized in that the plasma separation operation is performed at a pressure range that is completely different from the filtration pressure (i.e., transmembrane pressure difference) that is normally implemented. Even at that pressure, destruction of blood cell components (i.e.,
Hemolysis) does not occur.
血漿ライン側（濾液側）に負荷する防圧としては、通常
−５０ｍｍＨｇ 〜−１００ｍｍＨｇの範囲、好ましく
は−６５ｍ ｍ Ｈｇ 〜−８０ｍ ｍ Ｈｇの範囲で
用いられる。本発明では、このように濾液側に高度の防
圧を負荷して強制的に濾液、即ち血漿を得るようにして
、総蛋白等の篩い係数の良い血漿分離操作を行なうので
ある。The pressure applied to the plasma line side (filtrate side) is usually in the range of -50 mm Hg to -100 mm Hg, preferably in the range of -65 mm Hg to -80 mm Hg. In the present invention, a high pressure is applied to the filtrate side to forcibly obtain the filtrate, that is, plasma, thereby performing a plasma separation operation with a good sieving coefficient for total protein and the like.
また、本発明においては、血漿採取の実施に当り、血液
の抗凝固剤を適量使用する必要がある。Further, in the present invention, it is necessary to use an appropriate amount of a blood anticoagulant when collecting plasma.
尚、抗凝固作用を有する血液回路、血漿分離器が開発さ
れると、抗凝固剤による血漿の希釈が防止可能となる。If a blood circuit and a plasma separator with anticoagulant effects are developed, dilution of plasma by anticoagulants can be prevented.
抗凝固剤としては、体外血液潅流に使用できるものであ
れば、いずれでもよく、例えば、クエン酸（ＡＣＤ、Ｃ
ＰＤ等）、ヘパリン、プロスタグランジン、ＦＯＹ、Ｍ
Ｄ−８０５等が使用される。これらはその特性により献
血者へ注射することによって投与することもできる他、
穿針部、またはその下流側の血液ラインに分枝を設け、
そこから持続投与器、或いは点滴で投与することも可能
である。Any anticoagulant that can be used for extracorporeal blood perfusion may be used, such as citric acid (ACD, C
PD, etc.), heparin, prostaglandin, FOY, M
D-805 etc. are used. Due to their properties, these can be administered to blood donors by injection.
A branch is established in the blood line at or downstream of the puncture point,
It is also possible to administer from there via a continuous infusion device or an intravenous drip.
また、本発明に用いる血漿分離器としては、血漿分離速
度が大きく、血漿蛋白質の透過性が良好な、いずれの脱
型血漿分離器も使用可能であるが、中空糸膜型の分離膜
モジュールを使用することが好ましい。Furthermore, as the plasma separator used in the present invention, any deformed plasma separator that has a high plasma separation rate and good plasma protein permeability can be used, but a hollow fiber membrane type separation membrane module can be used. It is preferable to use
血漿゛分離膜モジュールに用いられる中空糸膜としては
、親水性を有するものが好ましく用いられるが、他方、
元来は疎水性であっても、界面活性剤又はコーティング
剤等により親水化処理したものも好ましく使用できる。As the hollow fiber membrane used in the plasma separation membrane module, one having hydrophilic properties is preferably used, but on the other hand,
Even if they are originally hydrophobic, those treated with a surfactant or coating agent to make them hydrophilic can also be preferably used.
更に、疎水性の中空糸膜な水と相溶性がよく表面張力の
小さい、例えばアルコールのような物質によって洗浄し
、生理食塩水等の無菌水、無塵水にて充填しておき、使
用に際して血液と置換することによって本発明の中空糸
膜として用いることができる。Furthermore, the membrane is a hydrophobic hollow fiber membrane that is highly compatible with water and has a low surface tension, washed with a substance such as alcohol, and filled with sterile water such as physiological saline or dust-free water before use. It can be used as the hollow fiber membrane of the present invention by replacing it with blood.
また、中空糸の材料としては、特に制限されるものでは
ない。高分子材料を素材とするものの例としては、ポリ
オレフィン（高密度ポリエチレン、ポリプロピレン、ポ
リ（４−メチル−ペンテン−１）など）、フッ素含有高
分子化合物、ポリスルホン、ポリカーボネート、ポリ塩
化ビニル、セルロースアセテート、ポリアクリロニトリ
ル、ボリビニルアルコール、ポリメチルメタアクリレー
ト、ポリアミド等の多孔質中空糸を挙げることができる
。また無機材料を素材とするものの例としては、ガラス
、セラミック、炭素等の多孔質中空糸を挙げることかで
きる。以上のうち、耐溶血性が高い点からポリオレフィ
ンを素材とする膜が好ましい。Furthermore, the material for the hollow fibers is not particularly limited. Examples of polymer materials include polyolefins (high-density polyethylene, polypropylene, poly(4-methyl-pentene-1), etc.), fluorine-containing polymer compounds, polysulfone, polycarbonate, polyvinyl chloride, cellulose acetate, Examples include porous hollow fibers such as polyacrylonitrile, polyvinyl alcohol, polymethyl methacrylate, and polyamide. Examples of materials made of inorganic materials include porous hollow fibers made of glass, ceramic, carbon, and the like. Among the above, membranes made of polyolefin are preferred because of their high resistance to hemolysis.
以上、中空糸膜を説明したが、耐溶血性の観点から、特
に、下記に示す多孔性中空糸膜な用いることか好ましい
。Hollow fiber membranes have been described above, but from the viewpoint of hemolysis resistance, it is particularly preferable to use the porous hollow fiber membranes shown below.
即ち、ポリオレフィンの多孔性中空糸膜であって、その
周壁部は、該中空糸膜の長さ方向に対し、略直角に走る
比較的太いロッド郡と、その各ロウド間に該中空糸膜の
長さ方向に走り且つ各ロッド間につながる微小フィブリ
ル郡とによって構成され、これらのロッド郡及び微小フ
ィブリル郡によって短冊状の微小孔部を形成してなり、
膜厚が５０〜１１００ｊＬ、内径が２５０〜４００ｇｍ
、且つバブルポイント法で測定したとき口径が０．２〜
１．０ＪＬｍである多孔性中空糸膜を、本発明の血漿分
離膜として使用することが好ましい。That is, it is a porous hollow fiber membrane of polyolefin, the peripheral wall of which has a group of relatively thick rods running approximately perpendicular to the length direction of the hollow fiber membrane, and a group of relatively thick rods running between the rods of the hollow fiber membrane. It is composed of a group of microfibrils running in the length direction and connected between each rod, and a strip-shaped micropore is formed by these rods and microfibrils,
Film thickness is 50-1100jL, inner diameter is 250-400gm
, and the diameter is 0.2 to 0.2 when measured by the bubble point method.
Preferably, a porous hollow fiber membrane of 1.0 JLm is used as the plasma separation membrane of the present invention.
そして、上記の多孔性中空糸膜はポリオレフィンの中空
糸を低温下、すなわち−６０°Ｃ以下、好ましくは一１
５０℃以下において延伸することによって作成される。The above-mentioned porous hollow fiber membrane is prepared by using polyolefin hollow fibers at low temperature, that is, below -60°C, preferably at -11°C.
It is created by stretching at 50°C or lower.
また、この延伸は、窒素、酸素、アルゴン、−酸化炭素
、メタンおよびエタンからなる郡から選ばれる媒体中で
行なうことが好ましい。The stretching is preferably carried out in a medium selected from the group consisting of nitrogen, oxygen, argon, carbon oxide, methane and ethane.
［実施例］
以下、本発明を実施例に基いて詳細に説明するが、本発
明がこれら実施例に限られるものてないことは明らかで
あろう。[Examples] Hereinafter, the present invention will be explained in detail based on Examples, but it will be clear that the present invention is not limited to these Examples.
（実施例、比較例）
ＡＣＤを加えた生血４文を用い、図面に示す血漿分離回
路により、濾液側の圧力を防圧（≦−５０ｍｍＨｇ）に
保持した場合と、通常の圧力（≧Ｏｍ ｍ Ｈｇ ）の
場合とにおける血漿分離操作を実施し、比較検討した。(Example, Comparative Example) Using 4 samples of raw blood to which ACD was added, the pressure on the filtrate side was maintained at a barrier pressure (≦-50 mmHg) and the case where the pressure on the filtrate side was maintained at a pressure-proof pressure (≧Om m Plasma separation operations were performed and compared in the case of Hg).
その結果を下表に示す。The results are shown in the table below.
尚、図面において、■は血漿分＃器、２は生血貯蔵タン
ク、３は赤血球濃厚液貯蔵タンク、４は分離血漿（濾液
）バッグ、５及び６はポンプを示す。又、Ｐ、、Ｐｏ及
びｐｒは各々圧力計を示す。In the drawings, ■ indicates a plasma separator, 2 indicates a fresh blood storage tank, 3 indicates a concentrated red blood cell storage tank, 4 indicates a separated plasma (filtrate) bag, and 5 and 6 indicate pumps. Further, P, Po and pr each represent a pressure gauge.
以上から明らかなように、通常圧力により血漿分離と、
高度防圧下の血漿分離とは、総蛋白、ＩｇＭ等の篩い係
数に差が認められた。しかも、このような高度の防圧下
における分離操作においても溶血は認められなかった。As is clear from the above, plasma separation using normal pressure,
Differences were observed in the sieving coefficients of total protein, IgM, etc. compared to plasma separation under high pressure. Moreover, no hemolysis was observed even during the separation operation under such high pressure.
［発明の効果］
以上説明したように、本発明の血漿分離方法によれば血
漿ライン側圧力を防圧に保持して分離操作を行なうこと
により、ＩｇＭ等の篩係数に優れた血漿を得ることかで
きる。[Effects of the Invention] As explained above, according to the plasma separation method of the present invention, plasma with excellent sieving coefficients such as IgM can be obtained by performing the separation operation while maintaining the pressure on the plasma line side at a pressure-proof level. I can do it.
図面は、血漿分離回路の例を示す概略説明図である。
１・・・血漿分離器、２・・・生血貯蔵タンク、３・・
・赤血球濃厚液貯蔵タンク、４・・・分離血漿（濾液）
バッグ、５・・・ポンプ。The drawing is a schematic explanatory diagram showing an example of a plasma separation circuit. 1...Plasma separator, 2...Live blood storage tank, 3...
・Red blood cell concentrate storage tank, 4...Separated plasma (filtrate)
Bag, 5...pump.
Claims (1)
器へ血液を輸送する送血ラインと、前記血漿分離器にお
いて血漿が分離された赤血球濃厚液を返送する返血ライ
ンと、前記分離された血漿を輸送する血漿ラインとから
なる血漿分離系における血漿分離に際し、前記血漿ライ
ン側圧力を陰圧に保持することを特徴とする血漿分離方
法。(1) a plasma separator with a built-in plasma separation membrane, a blood supply line for transporting blood to the plasma separator, a blood return line for returning the red blood cell concentrate from which plasma has been separated in the plasma separator; 1. A plasma separation method comprising: maintaining a pressure on the plasma line side at negative pressure during plasma separation in a plasma separation system comprising a plasma line for transporting separated plasma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62270718A JPH0773603B2 (en) | 1987-10-27 | 1987-10-27 | Plasma separator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62270718A JPH0773603B2 (en) | 1987-10-27 | 1987-10-27 | Plasma separator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01113067A true JPH01113067A (en) | 1989-05-01 |
| JPH0773603B2 JPH0773603B2 (en) | 1995-08-09 |
Family
ID=17489992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62270718A Expired - Lifetime JPH0773603B2 (en) | 1987-10-27 | 1987-10-27 | Plasma separator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0773603B2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5822068A (en) * | 1981-08-01 | 1983-02-09 | テルモ株式会社 | Filter type serum separator |
| JPS6185951A (en) * | 1984-10-04 | 1986-05-01 | 株式会社 ニツシヨ− | Membrane type serum separation system |
-
1987
- 1987-10-27 JP JP62270718A patent/JPH0773603B2/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5822068A (en) * | 1981-08-01 | 1983-02-09 | テルモ株式会社 | Filter type serum separator |
| JPS6185951A (en) * | 1984-10-04 | 1986-05-01 | 株式会社 ニツシヨ− | Membrane type serum separation system |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0773603B2 (en) | 1995-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100193172B1 (en) | Biological liquid treatment system and treatment method | |
| EP0266683B1 (en) | A blood components collector unit | |
| US4981596A (en) | System for treating blood for autotransfusion | |
| EP1016426B1 (en) | Leukocyte-removing filter material | |
| US5302299A (en) | Biological semi-fluid processing assembly | |
| JP2002526172A (en) | Biological fluid filters and systems | |
| JPH11267199A (en) | Blood treatment method and device | |
| JPH01113067A (en) | Separation of plasma | |
| JP3208132B2 (en) | Blood component separation method | |
| JPH01113068A (en) | Separation of plasma | |
| JPH01113066A (en) | Separation of plasma | |
| US20170266362A1 (en) | System for removal of pro-inflammatory mediators as well as granulocytes and monocytes from blood | |
| JP2010136803A (en) | System for removal of virus and cytokine from blood | |
| US20230173147A1 (en) | Blood separation system and blood products | |
| JP3180161B2 (en) | Separation method of hemolyzed blood | |
| JPH0197472A (en) | Multistage plasma separation method | |
| Philp et al. | Hemolysis reduction in plasmapheresis by module design: operating with pulsed flow filtration enhancement | |
| JPH02274262A (en) | Blood plasma collecting device | |
| JPS6384558A (en) | Plasma sampler | |
| JP3157519B2 (en) | Blood component separation system | |
| JPH019575Y2 (en) | ||
| JPH01160562A (en) | Plasma sampler | |
| JPS6353825B2 (en) | ||
| JPS6384560A (en) | Plasma sampling apparatus | |
| JPH01153164A (en) | Plasma sampler |